Related Experiment Video
Updated: Aug 9, 2026
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
Comparative study of commercially available anti-alpha-synuclein antibodies
E Croisier1, D Elfant MRes, M Deprez
1Department of Neuropathology, Imperial College London, London, UK.
Neuropathology and Applied Neurobiology
|April 28, 2006
Summary
Standardizing alpha-synuclein immunohistochemistry is crucial for diagnosing Parkinson's disease and related disorders. This study identified optimal antibodies and protocols for reliable detection of alpha-synuclein in neuropathology.
Area of Science:
- Neuropathology
- Neuroscience
- Immunohistochemistry
Background:
- Alpha-synuclein immunohistochemistry is key for diagnosing Parkinson's disease, Dementia with Lewy bodies, and Multiple System Atrophy.
- Existing protocols lack standardization, leading to variability in diagnostic accuracy.
- A review of 270 studies revealed only 31% used commercial antibodies, with inconsistent protocols.
Purpose of the Study:
- To establish a standardized protocol for alpha-synuclein immunohistochemistry in diagnostic neuropathology.
- To evaluate and compare seven commercial monoclonal antibodies for detecting alpha-synuclein.
- To determine optimal antigen unmasking methods for each antibody.
Main Methods:
- Reviewed 242 studies on alpha-synuclein immunohistochemistry in human tissue.
- Tested seven commercial monoclonal antibodies on brain tissue from patients with Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and controls.
- Assessed antibody performance based on immunolabelling intensity in various pathological features and non-specific staining.
Main Results:
- All tested antibodies detected alpha-synuclein inclusions.
- Significant differences were observed between antibodies, particularly in detecting glial inclusions.
- Antibodies targeting amino acids 116-131 and 15-123 showed superior performance.
Conclusions:
- Standardized protocols are needed for reliable alpha-synuclein detection in alpha-synucleinopathies.
- Specific antibodies targeting amino acids 116-131 and 15-123 are recommended for routine diagnostic practice.
- Further optimization of immunohistochemistry protocols will enhance diagnostic accuracy for neurodegenerative diseases.
